Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979609 | 0.91 | PTGDR2 (0.61) | PTGDR2PTGDRMAPK14RAB9AGAA | |
| SCHEMBL2982716 | 0.91 | MAPK14 (0.59) | PTGDR2MAPK14RAB9ANPC1MEN1 | |
| SCHEMBL2988954 | 0.89 | PTGDR2 (0.51) | PTGDR2PTGDRMAPK14RAB9ANPC1 | |
| SCHEMBL5132800 | 0.89 | PTGDR2 (0.55) | TRPV1PTGDR2PTGDRMAPK14GAA | |
| SCHEMBL2991956 | 0.88 | RAB9A (0.63) | PTGDR2MAPK14RAB9ANPC1MEN1 | |
| SCHEMBL2988202 | 0.88 | PTGDR2 (0.50) | TRPV1PTGDR2PTGDRMAPK14 | |
| SCHEMBL2982720 | 0.86 | PTGDR2 (0.60) | TRPV1PTGDR2PTGDRMAPK14 | |
| SCHEMBL2992207 | 0.85 | MAPT (0.52) | PTGDR2PTGDRMAPK14RAB9ANPC1 | |
| SCHEMBL2988704 | 0.85 | PTGDR2 (0.61) | PTGDR2PTGDRMAPK14RAB9ANPC1 | |
| SCHEMBL2986467 | 0.85 | PTGDR2 (0.51) | PTGDR2PTGDRMAPK14RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | claimed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | claimed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492437-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2057115-B9 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2057115-B9 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2057115-B1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2057115-B1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183289-B2 | 4-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2008024746-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173955-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | TRPV1 1152/4885PTGDR2 12/4885PTGDR 18/4885 |
| US-20120202854-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, CD74 | TRPV1 1152/4885PTGDR2 12/4885PTGDR 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.